Sartorius Stedim Biotech Presents A New Aseptic Disconnector: Clipster Makes Aseptic Tubing Disconnection Easy

Sartorius Stedim Biotech Presents A New Aseptic Disconnector: Clipster Makes Aseptic Tubing Disconnection Easy
 
Goettingen, Germany and Aubagne, France / b3c newswire / Sartorius Stedim Biotech, a leading international supplier for the pharma and biotech industries, has launched the Clipster Aseptic Disconnector. The new single-use device allows an aseptic disconnection of Silicone (Pt) tubing in biopharmaceutical manufacturing processes. It is safe, quick, easy to use and available as stand alone product or preassembled on single-use transfer lines and bag assemblies.

The Clipster Aseptic Disconnector is used after a fluid transfer to disconnect transfer lines and bag assemblies. The disconnection of tubes can be performed in non classified and classified environments while maintaining product sterility. It is performed with a hand-held tool which ensures easy execution in various space requirements. The Clipster Aseptic Disconnector can be applied to multiple sizes of Silicone tubing, such as 3/8"x 5/8" and 1/2" x 3/4".

The validation of this key single-use device has been carried out under the most stringent test regimes. Biological and physical tests were combined to provide data representing a variety of process conditions including critical applications.

About Sartorius Stedim Biotech
Sartorius Stedim Biotech is a leading provider of cutting-edge equipment and services for the development, quality assurance and production processes of the biopharmaceutical industry. Its integrated solutions covering fermentation, filtration, purification, fluid management and lab technologies are supporting the biopharmaceutical industry around the world to develop and produce drugs safely, timely and economically. Sartorius Stedim Biotech focuses on single-use technologies and value-added services to meet the rapidly changing technology requirements of the industry it serves. Strongly rooted in the scientific community and closely allied with customers and technology partners, the company is dedicated to its philosophy of "turning science into solutions". For more information, visit www.sartorius-stedim.com

Headquartered in Aubagne, France, Sartorius Stedim Biotech is listed on the Eurolist of Euronext Paris. With its own manufacturing and R&D sites in Europe, North America and Asia and a global network of sales companies, Sartorius Stedim Biotech enjoys a worldwide presence. Its key manufacturing and R&D site is in Germany. The company employs nearly 2,600 people, and in 2010 earned sales revenue of 432.9 million euros.

SOURCE: Sartorius Stedim Biotech

Suggested Articles

Novartis is rolling out positive interim phase 3 data on Zolgensma in Europe, which could support the recent launch of the SMA gene therapy there.

The new cost-cutting goal comes on top of a €2.6 billion annual savings target the company already laid out in a revamp initiated in 2018.

As hearings continued on Capitol Hill, a congressional committee said Novartis, Amgen and Mallinckrodt used routine price hikes to meet sales targets.